8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Aug 24, 2022)

Filed August 24, 2022For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced a key addition to its Board of Directors, electing Dr. Elliott Sigal to fill a newly created vacancy, expanding the Board to eleven members. Dr. Sigal's appointment is effective August 22, 2022, and he will serve as a Class I director with his term expiring at the 2023 annual meeting of stockholders. His election is a significant development as the company continues to grow and navigate the complex biotechnology landscape. Dr. Sigal's compensation as a non-employee director includes an annual cash fee of $55,000 and an initial stock option grant valued at $600,000, vesting over three years. He is also eligible for future annual stock option awards. This compensation structure aligns with industry practices for attracting experienced leadership to the board and signals the company's commitment to leveraging external expertise to drive strategic initiatives and enhance shareholder value.

Key Highlights

  • 1Dr. Elliott Sigal elected to the Board of Directors, expanding its size to eleven members.
  • 2Dr. Sigal's appointment is effective August 22, 2022, with his term expiring at the 2023 annual meeting.
  • 3As a non-employee director, Dr. Sigal will receive an annual cash fee of $55,000.
  • 4Dr. Sigal received an initial stock option grant valued at $600,000, vesting over three years.
  • 5Future annual stock option awards for Dr. Sigal are planned, valued at approximately $400,000 per year.
  • 6Dr. Sigal's compensation package includes vesting over time, aligning his interests with long-term shareholder value.
  • 7Dr. Sigal will enter into an indemnification agreement consistent with existing agreements for non-employee directors.

Frequently Asked Questions

Dr. Elliott Sigal is a newly elected Class I director to Alnylam Pharmaceuticals' Board. His appointment is significant as it expands the board and brings potentially valuable expertise to the company's strategic direction and governance. The filing does not detail his specific background, but typically board appointments of this nature are to enhance leadership and oversight.

Dr. Sigal will receive an annual cash fee of $55,000. He was also granted a stock option to purchase shares valued at $600,000 on the grant date, which will vest over three years. Beginning in 2023, he is eligible for annual stock option awards valued at approximately $400,000, vesting one year from the grant date.

The stock option grants are a form of compensation designed to align Dr. Sigal's interests with those of long-term shareholders. The initial grant vests ratably over three years, and future annual grants typically vest after one year, incentivizing sustained contribution and commitment to the company's performance and stock price appreciation.

This 8-K filing exclusively addresses Dr. Sigal's appointment and associated compensation. It does not provide information on Alnylam's financial performance or strategic shifts. Investors should refer to other SEC filings, such as the company's quarterly reports (10-Q) and annual reports (10-K), for comprehensive financial and strategic updates.